Has Benjamin Kitchens, MD received payments from drug or device companies?

Yes. Drug and device makers reported $383,479 in general payments to Benjamin Kitchens, MD across 525 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Benjamin Kitchens, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Benjamin Kitchens, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Benjamin Kitchens, MD

Hematology & Oncology · Dallas, TXNPI 1841637477

Payments from drug & device makers

$383,479in general payments, 2019–2025

Across 525 payments — averaging $730.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech, Inc.$126K
Jazz Pharmaceuticals Inc.$68K
Astellas Pharma US Inc$66K
Takeda Pharmaceuticals U.S.A., Inc.$28K
AbbVie$28K
Incyte Corporation$25K
plus $43K from 51 others

What the payments were for

Consulting fees$23,02213%
Speaking & faculty fees$119,29667%
Travel & lodging$22,25313%
Food & beverage$12,0997%
Education$3630%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech, Inc.	45	$125,558
Jazz Pharmaceuticals Inc.	38	$67,842
Astellas Pharma US Inc	87	$65,591
Takeda Pharmaceuticals U.S.A., Inc.	25	$28,415
AbbVie	43	$28,118
Incyte Corporation	52	$25,426
Ipsen Biopharmaceuticals, Inc	19	$18,373
AstraZeneca	35	$17,634
Genentech USA, Inc.	10	$1,434
Johnson & Johnson(2 entities)	14	$586
Merck	18	$523
Regeneron Healthcare Solutions, Inc.	8	$293
Eisai Inc.	13	$291
Pfizer	9	$265
Astellas Pharma Global Development	1	$216
Seagen Inc.	5	$215
Adaptive Biotechnologies Corporation	3	$206
GSK	3	$146
Boston Scientific	1	$145
E.r. Squibb & Sons, L.L.C.	11	$129
Servier Pharmaceuticals LLC	1	$128
Amgen	5	$116
Pharmacosmos Therapeutics Inc.	1	$115
Rigel Pharmaceuticals, Inc.	8	$111
Sanofi	1	$110
Karyopharm Therapeutics Inc.	5	$110
Blueprint Medicines Corporation	4	$89
AVEO Pharmaceuticals, Inc.	3	$79
Sobi, Inc	3	$77
Clovis Oncology, Inc.	1	$76
Bayer	3	$75
Syndax Pharmaceuticals, Inc.	3	$66
Gilead(2 entities)	3	$63
Dova Pharmaceuticals	3	$63
Iovance Biotherapeutics, Inc.	3	$61
Foundation Medicine, Inc.	3	$61
ADC Therapeutics America, Inc.	3	$59
Novartis	3	$56
Acrotech Biopharma Inc.	2	$52
Exelixis Inc.	2	$48
Array Biopharma Inc	2	$44
Epizyme, Inc.	3	$44
Boehringer Ingelheim	3	$44
Dendreon Pharmaceuticals LLC	1	$33
Genmab U.S., Inc.	2	$33
Deciphera Pharmaceuticals Inc.	1	$30
CSL Behring	2	$28
Pharmacyclics LLC, An Abbvie Company	1	$26
Taiho Oncology, Inc.	2	$26
Geron Corporation	1	$24
Sun Pharmaceutical Industries Inc.	1	$23
Tempus AI, Inc	1	$22
Immunocore Limited	1	$21
Mylan Specialty L.p.	1	$17
Morphosys, US Inc.	1	$15
Novo Nordisk	1	$15
Sirtex Medical Inc	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Vyloy$35,144
FRUZAQLA$28,212
ZYNYZ$24,365
ONIVYDE$18,025
ZIIHERA$14,246
IMFINZI$9,293
IMBRUVICA$238
TheraSphere Y90 Glass Microspheres 10 GBq$145
SOMATULINE DEPOT$131
TIBSOVO$128
LIBTAYO$126
clonoSEQ$125
MONJUVI$124
ADCETRIS$121
Monoferric$115
KEYTRUDA$114
ELITEK$110
ELIQUIS$103

How this compares

$383,479 in reported general payments places this provider in the 80th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$841,602

Medicare patients

285

Services billed

39,354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prochlorperazine Maleate	58	$1,835
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	54	$1,403
Ondansetron OdtOndansetron	43	$1,152
Tramadol Hcl	23	$787
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine	26	$396
Oxycodone Hcl	23	$330
Lidocaine-PrilocaineLidocaine/Prilocaine	25	$324
Pantoprazole Sodium	24	$307
Gabapentin	23	$175
Levothyroxine Sodium	16	$169
Mirtazapine	14	$159
Potassium Chloride	33	$144
Clobetasol Propionate	11	$118
Olanzapine	12	$87
Furosemide	19	$80

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Dallas

Prapti PatelDallas$10.3M
Farrukh AwanDallas$8.4M
Elizabeth MaherDallas$5.5M
Kevin CourtneyDallas$4.8M
Jaime BrugarolasDallas$2.8M
Syed KazmiDallas$2.5M
Elias JabbourHouston$264.1M
Luhua WangHouston$79.6M
Courtney DinardoHouston$74M
Jorge Cortes-FrancoHouston$59.4M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →